JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor ...
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, ...
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it ...
Dyne Therapeutics appoints Erick Lucera as CFO
Dyne Therapeutics (DYN) announced the appointment of Erick Lucera as CFO of Dyne, effective March 31. Lucera brings more than thirty years of ...
Dyne Therapeutics Names Editas Medicine's Lucera as CFO
Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at ...
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
BioSpace4d
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)
Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Chardan ...
Clinical Trials Arena on MSN4d
Dyne’s DMD trial advances patient mobility and dystrophin expression
The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.